OTC · Biotechnology

Adynxx, Inc. (ADYX) Stock

$0.00 OTC: ADYX Healthcare

Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions.

Valuation

MetricValue
Price$0.00
Market Cap$581
P/E Ratio0.00
P/B Ratio0.00
P/S Ratio0.00
EPS (TTM)$-10.26
52-Week High$0.00
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-100.00%
ROA-80.00%
ROCE-63.78%
Gross Margin-300.00%
Operating Margin-250.00%
Net Margin-400.00%
Debt/Equity0.00
Current Ratio9.00

Annual Financials (USD)

Metric20142015201620172018
Revenue$5.0M$15.0M$16.0M$2.0M$2.0M
Operating Profit$-25.0M$-28.0M$-31.0M$-5.0M$-5.0M
Net Profit$-25.0M$-26.0M$-28.0M$-26.0M$-8.0M
EPS$-104.36$-67.80$-60.60$-35.94$-10.26
Op Margin-531.1%-188.2%-191.4%-235.8%-239.0%

Balance Sheet (USD)

Metric20142015201620172018
Total Assets$30.0M$90.0M$54.0M$33.0M$10.0M
Total Liabilities$7.0M$37.0M$22.0M$17.0M$1.0M
Cash$17.0M$26.0M$6.0M$2.0M$9.0M
Borrowings$0$12.0M$12.0M$11.0M$0

Cash Flow (USD)

Metric20142015201620172018
Operating Cash Flow$-13.0M$-22.0M$-18.0M$-11.0M$-10.0M
Investing Cash Flow$-3.0M$-16.0M$1.0M$4.0M$29.0M
Financing Cash Flow$6.0M$0$-3.0M$-1.0M$0
Net Cash Flow$5.0M$9.0M$-20.0M$-3.0M$7.0M
Free Cash Flow$-14.0M$-22.0M$-19.0M$-11.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA2.60
FCF Yield-1671256.45%
Quick Ratio6.69
Interest Coverage0.00
Return 1Y0.00%
Return 3Y0.00%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BGMDBG Medicine, Inc. $0.00 — 0.00 $1137 0.00%
BIMIBIMI International Medical Inc. $0.00 — 0.00 $1156 0.00%
BNKLBionik Laboratories Corp. $0.00 — 0.00 $1248 0.00%
CFRXQContraFect Corp. $0.00 — 0.00 $107 0.00%
EFTReFFECTOR Therapeutics, Inc. $0.00 — 0.00 $2352 0.00%

About Adynxx, Inc.

Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort. Additionally, AYX2 is a pre-clinical candidate being explored for its potential in treating localized chronic pain. Established in 2007, the company's corporate headquarters are situated in San Francisco, California.

Adynxx, Inc. (ADYX) stock trades at $0.00 with a market capitalization of $581. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Adynxx, Inc. generates a return on equity (ROE) of -100.00%, return on capital employed of -63.78%, an operating margin of -250.00%, a net profit margin of -400.00%.

Official website: www.adynxx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides